MacroGenics, Inc.
$3.48
▲
5.86%
2026-04-21 08:08:01
www.macrogenics.com
NMS: MGNX
Explore MacroGenics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$228.17 M
Current Price
$3.48
52W High / Low
$3.88 / $1.11
Stock P/E
—
Book Value
$0.88
Dividend Yield
—
ROCE
-34.08%
ROE
-86.94%
Face Value
—
EPS
$-1.18
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
293
Beta
1.1
Debt / Equity
66.13
Current Ratio
5.1
Quick Ratio
4.92
Forward P/E
-3.71
Price / Sales
1.53
Enterprise Value
$75.65 M
EV / EBITDA
-1.15
EV / Revenue
0.51
Rating
None
Target Price
$3.6
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Omeros Corporation | $13.47 | — | $997.87 M | — | -49.6% | 2.21% | $17.65 / $2.95 | $-1.69 |
| 2. | Cardiff Oncology, Inc. | $1.78 | — | $123.06 M | — | -107.63% | -71.45% | $4.55 / $1.48 | $0.66 |
| 3. | Context Therapeutics Inc. | $2.26 | — | $223.27 M | — | -65.65% | -46.39% | $3.62 / $0.49 | $0.66 |
| 4. | Lantern Pharma Inc. | $2.76 | — | $27.91 M | — | -275.14% | -1.24% | $5.74 / $1.11 | $0.58 |
| 5. | Relay Therapeutics, Inc. | $16.4 | — | $3 B | — | -50.82% | -41.12% | $17.32 / $2.53 | $3.26 |
| 6. | Skye Bioscience, Inc. | $0.78 | — | $26.15 M | — | -289.25% | -1.27% | $5.75 / $0.57 | $0.6 |
| 7. | Sensei Biotherapeutics, Inc. | $31.39 | — | $42.07 M | — | -119.5% | -74.01% | $36.76 / $5.25 | $18.24 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 41.23 M | 72.84 M | 22.24 M | 13.19 M | 17.73 M | — |
| Operating Profit | -12.1 M | 18.64 M | -36.76 M | -42.62 M | -52.84 M | — |
| Net Profit | -14.15 M | 16.82 M | -36.25 M | -41.04 M | -15.42 M | — |
| EPS in Rs | -0.22 | 0.26 | -0.57 | -0.65 | -0.24 | 0.9 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 149.5 M | 149.96 M | 58.75 M | 150.02 M |
| Operating Profit | -72.84 M | -110.58 M | -168.24 M | -121.42 M |
| Net Profit | -74.62 M | -66.97 M | -9.06 M | -119.76 M |
| EPS in Rs | -1.17 | -1.05 | -0.14 | -1.88 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 256.85 M | 261.65 M | 298.42 M | 280.47 M |
| Total Liabilities | 201.25 M | 145.6 M | 145.81 M | 138.46 M |
| Equity | 55.59 M | 116.06 M | 152.61 M | 142.01 M |
| Current Assets | 219.94 M | 217.49 M | 251.34 M | 222.18 M |
| Current Liabilities | 43.12 M | 55.53 M | 56.11 M | 48.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -81.04 M | -68.37 M | -78.2 M | -86.96 M |
| Investing CF | -114.1 M | 149.3 M | -80.08 M | 70.72 M |
| Financing CF | 69.51 M | 0.96 M | 150.36 M | 1.66 M |
| Free CF | -82.95 M | -72.08 M | -79.97 M | -90.58 M |
| Capex | -1.91 M | -3.71 M | -1.76 M | -3.62 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 155.26% | -60.84% | — | — |
| Earnings Growth % | -639.3% | 92.44% | — | — |
| Profit Margin % | -44.66% | -15.42% | -79.83% | — |
| Operating Margin % | -73.74% | -286.38% | -80.94% | — |
| Gross Margin % | 91.8% | 86% | 95.08% | — |
| EBITDA Margin % | -38.25% | 3.43% | -71.92% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.